The April 2023 catch-up price reductions are causing significant concern across the biopharmaceutical sector and while the framework has captured many recently reimbursed brands it has the appearance of targeting one particular group of medicines. …
The appearance of a pricing policy targeting one group of medicines
August 19, 2022 Latest NewsBioPharma
Latest Video
New Stories
-
Australia leads the way as Moderna and MSD take personalised cancer vaccine into lung cancer
October 24, 2026 - - Latest News -
Arrotex bets on Recce's Phase 3 gel as diabetic foot infections get harder to treat
October 23, 2026 - - Latest News -
The imperative is to negotiate with the fifth year of the agreement in mind
October 23, 2026 - - Latest News -
The private medicines boom has mostly passed vaccines by, for now
October 23, 2026 - - Latest News -
BioNTech opens mRNA plant, putting Melbourne's north on the biotech map
October 22, 2026 - - Latest News -
The industry walked out on Britain, and what it cost to win them back
October 22, 2026 - - Latest News -
An architect of the first industry–Commonwealth medicines pact to lead CSL
October 21, 2026 - - Latest News